Microbiota of melanoma patients treated with immunotherapy

Next-generation sequencing (NGS) data of V3-V4 16S rDNA fragment amplicons of (metadata - column 'Source') total fecal microbiota ('stool'), fecal SIgA fraction ('Ig-bound'), and plasma ('plasma') of melanoma patients treated with: anti-PD-1 immunotherapy (metadata - 'ICI' in column 'Group') or experimental genetically modified melanoma vaccine (metadata - 'GMV' in column 'Group'), and control group (metadata - 'C' in column 'Group'). The samples were colected before implementation of therapy (metadata - '0' in column 'Stage') and at 6th to 12th day after vaccine infusion (metadata - '1' in column 'Stage' for GMV treated patients) or after PD1 checkpoint inhibitor infusion - 3 months (metadata - '1' in column 'Stage' for ICI treated patients), 6 months (metadata - '2' in column 'Stage' for ICI treated patients), 9 months (metadata - '3' in column 'Stage' for ICI treated patients), and 12 months (metadata - '4' in column 'Stage' for ICI treated patients). The ICI patients were evaluated for response to the treatment: responding (metadata - 'R' in column 'Response') and non-responding (metadata - 'NR' in column 'Response'). Missing data was described with 'NA'.